-- イベルドローラ傘下のスコティッシュパワー・リニューアブルズとアブダビのマスダールは、総工費40億ポンド(41億ドル)のイースト・アングリア・スリー洋上風力発電所において、最初のタービンを設置したと火曜日に発表した。 このプロジェクトで使用されるシーメンス・ガメサ製の14MWタービンは、ブレード長115メートルで、英国海域で製造・設置されたものとしては過去最長となる。95基のタービンからなるこのプロジェクトで使用される285枚のブレードはすべて、シーメンス・ガメサのハル工場で製造された。 サフォーク沖に位置するイースト・アングリア・スリーは、完成時には総発電容量1.4ギガワットとなり、英国の130万世帯以上の電力需要を賄うのに十分な電力を供給する予定だ。 マスダールによると、各タービンの高さは約262メートルで、英国の一般家庭1軒を4日以上稼働させるのに十分な電力を発電できると推定されている。 このプロジェクトは、本格稼働時には世界最大級の洋上風力発電所の一つとなり、英国のクリーンエネルギー目標と洋上風力発電拡大戦略に大きく貢献することが期待されている。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%